Cookies on the KCI website
We use cookies to improve your browsing experience on our website. Please visit Privacy Policy our for more information about cookies and how we use them. We recommend you to accept the use of cookies for better navigation.
Accessibility Help | Sitemap | Contact Us | Customer Support Ireland Freephone 1 800 33 33 77
Ireland Change Country
Home  |  Conditions  |  Products  |  Clinical Evidence  |  Education & Training  |  For Patients  |  Customer Support
You are here: Home > News & Media > Media Information > KCI Milestones
Print

KCI Milestones

2011

APAX Partners-led consortium acquires KCI. KCI launches the V.A.C.Ulta™ Negative Pressure Wound Therapy System, and introduces Graftjacket® regenerative tissue matrix (RTM) and Graftjacket flowable soft tissue scaffold (FSTS).
KCI celebrates its 35th Anniversary with the groundbreaking of its new global corporate headquarters in San Antonio, Texas.

2010

KCI launches new innovations, including the Prevena™ Incision Management System, the first powered negative pressure product designed specifically for the management of clean, closed surgical incisions.
The company opens its global shared service center in Budapest, Hungary, and a KCI office in Japan.

2009

KCI launches ABThera™ Open Abdomen Negative Pressure Therapy (OA NPT) System. The ABThera™ System addresses patient quality of life through an easy-to-use system designed to assist surgeons in the management and treatment of Abdominal Compartment Syndrome (ACS) and to help achieve primary fascial closure.

KCI introduces V.A.C.® GranuFoam™ Bridge Dressing, further expanding the portfolio of dressings used in the treatment of chronic wounds. This new dressing simplifies application in chronic wounds, especially Diabetic Foot Ulcers (DFUs) where it is compatible with off-loading devices.

2007

KCI introduces third-generation InfoV.A.C.® and ActiV.A.C.® Therapy Systems globally, the only NPWT systems specifically cleared for use in all care settings, including home use.

KCI establishes a global manufacturing facility in Athlone, Ireland.

2005

KCI expands into Denmark and the Middle East.

2004

KCI is listed on the New York Stock Exchange.

2000

KCI receives approval for Medicare Part B reimbursement for V.A.C.® Therapy. This approval makes the innovative V.A.C.® Therapy System available to elderly and disabled home care patients in the United States.

Several “next-generation” V.A.C.® Therapy products are introduced.

1996

KCI launches its greatest innovation to date: the V.A.C.® Therapy System, which is clinically demonstrated to promote wound healing while reducing the overall cost of treating patients with complex wounds.

1995

KCI introduces first medical device that provides foot compression therapy to prevent deep vein thrombosis.

1990

KCI opens sales offices in Germany, France and the Netherlands.

1989

KCI opens first international sales offices in Canada and the UK.

1976

Dr. Jim Leininger, an accident and emergency physician, purchases the manufacturing rights to a critical care bed, and with a few employees, founds Kinetic Concepts, Inc.

For more information, contact:

Kinetic Concepts, Inc.
Media Relations:
Media@kci1.com for journalists only.

This Web page contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.


Updated: 2 November 2012


  • Share on Facebook.com
  • Share on Twitter
  • Visit our YouTube page

Important Message for Patients

Legal Notice | Privacy Policy | Contact Us


Copyright © 1998 – 2013 KCI Licensing, Inc All Rights Reserved.   DSL# 09-03-193.IE

The information included in this Web site has been prepared for and is intended for viewing exclusively within the Republic of Ireland. This Web site contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications and restriction in different countries.